3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
Bevacizumab
14
Carboplatin
12
Standard of Care
10
Nivolumab
9
Cyclophosphamide
9
Cetuximab
8
Pemetrexed
7
Exercise
7
Doxorubicin
7
durvalumab
6
atezolizumab
6
Temozolomide
6
Radiotherapy
6
Prednisone
6
Paclitaxel
6
Cisplatin
6
Blood Specimen Collection
6
abemaciclib
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
olaparib
4
dostarlimab
4
Rituximab
4
Leucovorin
4
Gemcitabine
4
Fulvestrant
4
Docetaxel
4
Dexamethasone
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
4-hydroxy-N-desmethyltamoxifen
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled